Clinical Trials
5 trialsNCT00321581 2019-11-21
AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00475150 2017-02-15
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2 Completed
NCT00458731 2014-02-19
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00321724 2013-01-15
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00502385 2011-01-21
Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML
AstraZeneca
Phase 1 Completed